133 
1 the NIH, and other types of interchange at the national 
2 level and the local level, provide sufficient safety 
3 for monitoring the activities, the biohazards committee. 
4 Thank you. 
5 MR. LIBASSI: Thank you. 
6 Carl Anderson? 
7 DR. ANDERSON: My name is Carl Anderson. I am 
8 a research scientist in the Biology Department at Brookhaven 
9 National Laboratory. I should like to speak to you in favor 
10 of the proposed revisions to the NIH guidelines for recom- 
H binant DNA. 
12 I have a degree in microbiology, and for the 
13 past eight years my research has concerned molecular 
14 aspects of the replication of DNA tumor viruses. I operate 
15 a P 3 facility at the Brookhaven National Laboratory. That 
15 facility has been used primarily for handling moderate- 
17 risk tumor viruses during the past three years. 
18 Although my experience with recombinant DNA 
19 technology is not terribly extensive, I have been involved 
2Q in cloning specific DNA fragments, and I have been 
21 involved in research which has made use of recombinant 
22 DNA. I am not now engaged in any specific project involving 
23 recombinant DNA, however. 
24 About a year ago I organized a symposium at the 
25 Brookhaven National Laboratory which considered the prospects 
[225] 
